Cannabinoid receptors (CB1/CB2), TRPV1, and other targets
Assets acting on this target.
- Class
- Phytocannabinoid
- Notes
- mechanism wave 2026-08-24 (PubMed co-occurrence, 18 article(s)); source: https://pubmed.ncbi.nlm.nih.gov/42129940/
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| GWP42006 (Cannabidivarin) | Jazz Pharmaceuticals | Cannabinoid receptors (CB1/CB2), TRPV1, and other targets | Epilepsy | Ph 2 | EfficacyGW Pharmaceuticals' Phase 2a trial of GWP42006 (162 adults with inadequately controlled focal seizures) failed to outperform placebo on its primary endpoint, ending development of this candidate for epilepsy. | source ↗ |